DENALI THERAPEUTICS INC's ticker is DNLI and the CUSIP is 24823R105. A total of 188 filers reported holding DENALI THERAPEUTICS INC in Q1 2022. The put-call ratio across all filers is 2.00 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2023 | $283,326 | +28.1% | 9,601 | 0.0% | 0.19% | +19.1% |
| Q1 2023 | $221,207 | -17.2% | 9,601 | 0.0% | 0.16% | -83.2% |
| Q4 2022 | $267,004 | -9.5% | 9,601 | 0.0% | 0.93% | -3.8% |
| Q3 2022 | $295,000 | +4.2% | 9,601 | 0.0% | 0.97% | +40.0% |
| Q2 2022 | $283,000 | -8.4% | 9,601 | 0.0% | 0.69% | +30.0% |
| Q1 2022 | $309,000 | -27.8% | 9,601 | 0.0% | 0.53% | +9.9% |
| Q4 2021 | $428,000 | -0.7% | 9,601 | +12.3% | 0.48% | +7.8% |
| Q3 2021 | $431,000 | -35.8% | 8,551 | 0.0% | 0.45% | -41.2% |
| Q2 2021 | $671,000 | – | 8,551 | – | 0.76% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Crestline Management, LP | 19,462,500 | $339,037,000 | 35.95% |
| Euclidean Capital LLC | 323,749 | $27,117,000 | 5.74% |
| Flagship Pioneering Inc. | 2,730,263 | $228,687,000 | 4.16% |
| Casdin Capital, LLC | 1,310,000 | $109,726,000 | 3.25% |
| A.R.T. Advisors, LLC | 6,173 | $517,000 | 2.39% |
| MARK ASSET MANAGEMENT LP | 172,040 | $14,410,000 | 1.73% |
| Temasek Holdings (Private) Ltd | 4,410,457 | $369,420,000 | 1.59% |
| Integral Health Asset Management, LLC | 57,500 | $4,816,000 | 1.43% |
| GILDER GAGNON HOWE & CO LLC | 3,219,843 | $269,694,000 | 1.34% |
| IRONWOOD INVESTMENT MANAGEMENT LLC | 19,365 | $1,622,000 | 0.95% |